{
    "clinical_study": {
        "@rank": "8224", 
        "arm_group": {
            "arm_group_label": "18-FDG PET/CT, DWI, DCE-MRI", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The standard treatment for cervix cancer at Princess Margaret Hospital is external radiation\n      with chemotherapy followed by internal radiation, called brachytherapy. Currently,\n      brachytherapy treatment is planned on a type of Magnetic Resonance Imaging (MRI) called\n      T2-weighted (T2W) MRI.\n\n      The main purpose of this study is to determine whether the following imaging tests can\n      visualize the tumor better for planning the brachytherapy treatment:\n\n        1. special types of MRI called diffusion weighted MRI (DWI) and dynamic-contrast enhanced\n           MRI (DCE-MRI); and\n\n        2. an x-ray test called positron emission test (PET) performed with a sugar dye called\n           FDG. MRI-guided brachytherapy is resource-intensive and not widely available."
        }, 
        "brief_title": "MRI FDG PET Imaging Cervix", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer Squamous Cell", 
        "condition_browse": {
            "mesh_term": [
                "Uterine Cervical Neoplasms", 
                "Neoplasms, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 18 years\n\n          2. Histologic diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous\n             carcinoma of the cervix\n\n          3. FIGO Stage IB - IVA\n\n          4. Intention to treat using radiotherapy with or without concurrent cisplatin\n             chemotherapy according to the current treatment policies of the PMH Gynecology Group\n\n          5. Intention to treat with MR-guided brachytherapy as part of standard radiotherapy\n             according to the current treatment policies of the PMH Gynecology Group\n\n          6. No cytotoxic anti-cancer therapy for cervix cancer prior to study entry\n\n          7. A negative urine or serum pregnancy test within the two week interval immediately\n             prior to the first PET-CT imaging, in women of child-bearing age\n\n          8. Ability to provide written informed consent to participate in the study\n\n        Exclusion Criteria:\n\n          1. Prior complete or partial hysterectomy\n\n          2. Carcinoma of the cervical stump\n\n          3. Inability to lie supine for more than 30 minutes\n\n          4. Insulin-dependent diabetes mellitus\n\n          5. Impaired kidney function with glomerular filtration rate < 30\n\n          6. Previous anaphylactic reaction to gadolinium or other contraindications to MR."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899404", 
            "org_study_id": "UHN REB 12-5221-C"
        }, 
        "intervention": {
            "arm_group_label": "18-FDG PET/CT, DWI, DCE-MRI", 
            "description": "All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.", 
            "intervention_name": "18-FDG PET/CT, DWI, DCE-MRI", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cervical Cancer", 
            "PET Scan for cervix", 
            "MRI for cervix"
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "contact": {
                "email": "Michael.Milosevic@rmp.uhn.on.ca", 
                "last_name": "Michael Milosevic, MD", 
                "phone": "416 946 4501", 
                "phone_ext": "2932"
            }, 
            "contact_backup": {
                "email": "Kathy.Han@rmp.uhn.on.ca", 
                "last_name": "Kathy Han, MD", 
                "phone": "416 946 4501", 
                "phone_ext": "2919"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5G 2M9"
                }, 
                "name": "University Health Network, The Princess Margaret"
            }, 
            "investigator": [
                {
                    "last_name": "Michael Milosevic, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Anthony Fyles, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Prospective Study of the Utility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted MRI (DWI)and Positron Emission Tomography (PET) Imaging With 18F-Fluorodeoxyglucose (18FDG) in Brachytherapy for Cervix Cancer", 
        "overall_contact": {
            "email": "Michael.Milosevic@rmp.uhn.on.ca", 
            "last_name": "Michael Milosevic, MD", 
            "phone": "416 946 4501", 
            "phone_ext": "2932"
        }, 
        "overall_contact_backup": {
            "email": "Kathy.Han@rmp.uhn.on.ca", 
            "last_name": "Kathy Han, MD", 
            "phone": "416 946 4501", 
            "phone_ext": "2919"
        }, 
        "overall_official": {
            "affiliation": "University Health Network, The Princess Margaret", 
            "last_name": "Michael Milosevic, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Target delineation in brachytherapy using standard T2-weighted MRI versus DCE-MRI, DWI and FDG-PET/CT imaging: gross tumor volume and high-risk clinical target volume in patients with cervical cancer", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "This objective will evaluate the potential for translation of this technique to centres with limited MRI access.", 
                "measure": "Target delineation using standard MRI acquired during the last week of EBRT fused to planning CT versus full MRI-guided brachytherapy.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Follow-up imaging (MRI and 18FDG PET) versus the imaging done at the time of brachytherapy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Imaging techniques for visualizing the brachytherapy applicator.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "collaborator": {
                "agency": "Princess Margaret Hospital, Canada", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}